Financial Survey: Tetralogic Pharmaceuticals Corp (TLOG) and Its Peers
Tetralogic Pharmaceuticals Corp (NASDAQ: TLOG) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Tetralogic Pharmaceuticals Corp to related companies based on the strength of its profitability, earnings, analyst recommendations, institutional ownership, valuation, risk and dividends.
Institutional & Insider Ownership
2.7% of Tetralogic Pharmaceuticals Corp shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 24.0% of Tetralogic Pharmaceuticals Corp shares are held by insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Tetralogic Pharmaceuticals Corp and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Tetralogic Pharmaceuticals Corp||N/A||-$21.14 million||-0.02|
|Tetralogic Pharmaceuticals Corp Competitors||$224.58 million||$57.96 million||-1.20|
Tetralogic Pharmaceuticals Corp’s competitors have higher revenue and earnings than Tetralogic Pharmaceuticals Corp. Tetralogic Pharmaceuticals Corp is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations and price targets for Tetralogic Pharmaceuticals Corp and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tetralogic Pharmaceuticals Corp||0||0||0||0||N/A|
|Tetralogic Pharmaceuticals Corp Competitors||123||465||1163||11||2.60|
As a group, “Biotechnology” companies have a potential upside of 58.96%. Given Tetralogic Pharmaceuticals Corp’s competitors higher possible upside, analysts plainly believe Tetralogic Pharmaceuticals Corp has less favorable growth aspects than its competitors.
This table compares Tetralogic Pharmaceuticals Corp and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-73.81%|
|Tetralogic Pharmaceuticals Corp Competitors||-910.58%||-183.99%||-27.07%|
Risk & Volatility
Tetralogic Pharmaceuticals Corp has a beta of 3, meaning that its share price is 200% more volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals Corp’s competitors have a beta of 1.13, meaning that their average share price is 13% more volatile than the S&P 500.
Tetralogic Pharmaceuticals Corp competitors beat Tetralogic Pharmaceuticals Corp on 5 of the 9 factors compared.
Tetralogic Pharmaceuticals Corp Company Profile
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.